Corpus Uteri Cancer in Kazakhstan: Recent Incidence Trends.
Incidence
Kazakhstan
Trends
cartogram
corpus uteri cancer
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Mar 2023
01 Mar 2023
Historique:
received:
25
04
2022
medline:
29
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
Endometrial cancer is the fifteenth most common malignant disease in the world. It is estimated that 417,367 new cases of this malignant neoplasm are diagnosed annually and 97,370 women die from it. The epidemiological features of the corpus uteri cancer (CUC) incidence and its spatial and temporal assessment in Kazakhstan were studied. The retrospective study was done for the period 2009-2018. Descriptive and analytical methods of epidemiology were used. Crude, age-specific, age-standardized, equalized incidence rates and approximation were calculated. The method of drawing up a cartogram based on the determination of the standard deviation (σ) from the mean (x) was applied. During the study period, 10,522 new cases of CUC were registered. The average annual age-standardized incidence rate was 11.1±0.2 cases per 100,000 population of female, (Т=+0.6%; R2=0.083). The analysis of ASIR showed unimodal growth with a peak at 65-69 years - 58.8±3.6 cases per 100,000 population of female. The most pronounced downward trend was revealed in the age group < 30 years (T=-2.6%), and the most pronounced annual average upward rates was in 80-84 years (T=+6.4%). The results of the spatial analysis showed regions with a higher levels of CUC incidence rate per 100,000 population of female: Pavlodar, Kostanay, Karaganda, Almaty city, North Kazakhstan and Astana city. In recent years, CUC incidence in Kazakhstan has been increasing. High incidence rates were found in the northern regions of the country, and the trend of incidence growth was more pronounced in the western and eastern regions.
Sections du résumé
BACKGROUND
BACKGROUND
Endometrial cancer is the fifteenth most common malignant disease in the world. It is estimated that 417,367 new cases of this malignant neoplasm are diagnosed annually and 97,370 women die from it.
OBJECTIVE
OBJECTIVE
The epidemiological features of the corpus uteri cancer (CUC) incidence and its spatial and temporal assessment in Kazakhstan were studied.
METHODS
METHODS
The retrospective study was done for the period 2009-2018. Descriptive and analytical methods of epidemiology were used. Crude, age-specific, age-standardized, equalized incidence rates and approximation were calculated. The method of drawing up a cartogram based on the determination of the standard deviation (σ) from the mean (x) was applied.
RESULT
RESULTS
During the study period, 10,522 new cases of CUC were registered. The average annual age-standardized incidence rate was 11.1±0.2 cases per 100,000 population of female, (Т=+0.6%; R2=0.083). The analysis of ASIR showed unimodal growth with a peak at 65-69 years - 58.8±3.6 cases per 100,000 population of female. The most pronounced downward trend was revealed in the age group < 30 years (T=-2.6%), and the most pronounced annual average upward rates was in 80-84 years (T=+6.4%). The results of the spatial analysis showed regions with a higher levels of CUC incidence rate per 100,000 population of female: Pavlodar, Kostanay, Karaganda, Almaty city, North Kazakhstan and Astana city.
CONCLUSION
CONCLUSIONS
In recent years, CUC incidence in Kazakhstan has been increasing. High incidence rates were found in the northern regions of the country, and the trend of incidence growth was more pronounced in the western and eastern regions.
Identifiants
pubmed: 36974537
doi: 10.31557/APJCP.2023.24.3.849
pmc: PMC10334102
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
849-857Références
J Indian Med Assoc. 2009 Jun;107(6):403-5
pubmed: 19886379
Asian Pac J Cancer Prev. 2021 Apr 01;22(4):1295-1304
pubmed: 33906325
Lancet Oncol. 2015 Sep;16(9):1061-1070
pubmed: 26254030
Obstet Gynecol Sci. 2020 Mar;63(2):141-149
pubmed: 32206653
Arch Gynecol Obstet. 2010 Apr;281(4):717-21
pubmed: 19787362
Iran J Public Health. 2016 Aug;45(8):1012-1019
pubmed: 27928527
Onco Targets Ther. 2016 Sep 07;9:5521-30
pubmed: 27660470
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Int J Cancer. 2019 Oct 1;145(7):1719-1730
pubmed: 30387875
Asian Pac J Cancer Prev. 2021 Sep 01;22(9):2807-2817
pubmed: 34582649
Hum Reprod Update. 2014 Sep-Oct;20(5):748-58
pubmed: 24688118
Adv Gerontol. 2017;30(4):505-515
pubmed: 28968024
Cancer Epidemiol. 2013 Aug;37(4):374-7
pubmed: 23591011
N Engl J Med. 2020 Nov 19;383(21):2053-2064
pubmed: 33207095
BMC Cancer. 2019 May 31;19(1):527
pubmed: 31151429
J Natl Cancer Inst. 2018 Apr 1;110(4):354-361
pubmed: 29045681
Mech Ageing Dev. 2017 Jun;164:113-126
pubmed: 28502820
Indian J Cancer. 2017 Jan-Mar;54(1):388-391
pubmed: 29199729
J Steroid Biochem Mol Biol. 2014 Jul;142:83-9
pubmed: 23680641
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50
pubmed: 30306580
Eur J Surg Oncol. 2016 Feb;42(2):166-75
pubmed: 26647302
Acta Oncol. 2016;55 Suppl 1:65-73
pubmed: 26784001